Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial

Key Points

This trial evaluates the effectiveness of nivolumab and ipilimumab in advanced bile duct cancers, focusing on the response in gallbladder cancer patients.
Phase II clinical trial assessing combined nivolumab and ipilimumab treatment.
Involved a large cohort of patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer.
Focus on the response rates and toxicity associated with the combination therapy.
Combined anti-CTLA-4/PD-1 treatment showed limited efficacy in the overall cohort.
Encouraging activity observed specifically in the gallbladder cancer subgroup.
Results suggest the need for further evaluation of checkpoint inhibitors in gallbladder cancer patients.

Answers are grounded in this paper and cite their sources.

Phase II trial shows limited efficacy in cholangiocarcinoma, with encouraging results in gallbladder cancer.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Nagrial et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share